1996
- --------------------------------------------------------------
PruTech Research and Annual
Development Partnership III Report
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
LETTER TO UNITHOLDERS FOR THE YEAR ENDED DECEMBER 31, 1996
1
PRUTECH III PORTFOLIO
The following investments and/or royalty rights were active during the year, or
had value at the end of the year. The Partnership's position in each investment
is as of December 31, 1996. Certain of the securities held by the Partnership
have restrictions on resale due to Federal Securities laws and regulations, and
as noted below, certain of these securities have been sold subsequent to
December 1996.
CREATIVE BIOMOLECULES, INC. (CBMI)
Position: 509,382 shares of common stock; director's option for 6,900 shares of
common stock exercisable at $8.50 per share; royalty rights on soft
tissue growth factor products which expire December 1999
While work continues on several of the Partnership's projects, given the time
required for regulatory approvals it appears unlikely that these projects will
produce sales royalties for the Partnership as the Partnership's royalty rights
expire in 1999. During December 1996, the Partnership sold 214,900 shares of
Creative BioMolecules, Inc. common stock generating $2,276,000 for the
Partnership.
During January and February 1997, the Partnership sold 441,898 shares of
Creative BioMolecules, Inc. common stock for $5,019,000. Additionally, the
Partnership exercised its director's option during the first quarter of 1997.
The stock price of CBMI was $8.75 per share as of March 20, 1997.
FOREST LABORATORIES, INC. (FRX)
Position: Royalty rights to a treatment for Alzheimer's disease which expire
December 1999
Clinical studies on the treatment for Alzheimer's disease, being developed by
Forest Laboratories, Inc., were completed during 1996. The filing of a New Drug
Application with the FDA is expected in 1997. During the first quarter of 1996,
the Partnership sold its remaining 75,000 shares of Forest common stock
generating $3,600,000 for the Partnership.
KOPIN CORPORATION (KOPN)
Position: 537,333 shares of common stock
During the second quarter of 1996, the Partnership received a $433,334
minimum royalty payment from its royalty positions on Gallium Arsenide and LED
products. As a result, the Partnership holds no technology or royalty positions
with Kopin and, therefore, no further royalties will be received by the
Partnership from Kopin. During the first quarter of 1996, the Partnership sold
4,334 shares of Kopin stock for $60,000.
From January 15, 1997 through March 14, 1997, the Partnership sold 82,189
shares of Kopin Corporation common stock for $1,037,000. The stock price of
Kopin was $14.00 per share as of March 20, 1997.
SOMATIX THERAPY CORPORATION (SOMA)
Position: 500,000 shares of common stock
In January 1997, Somatix announced that it was being acquired by Cell Genesys
(CEGE). Somatix shareholders are to receive .385 shares of Cell Genesys stock
for each share of Somatix stock. This transaction is expected to close in April
1997. Between January 28, 1997 and February 3, 1997, the Partnership sold
205,000 shares of Somatix Therapy Corporation common stock for $517,000. The
stock price of Somatix was $2.00 per share as of March 20, 1997.
2
1177 Avenue of the Americas Telephone 212 596 7000
New York, NY 10036 Facsimile 212 596 8910
Price Waterhouse LLP (LOGO)
REPORT OF INDEPENDENT ACCOUNTANTS
February 13, 1997
To the Partners of PruTech Research and Development Partnership III
In our opinion, the accompanying statement of financial condition and the
related statements of operations, of changes in partners' capital and cash flows
present fairly, in all material respects, the financial position of PruTech
Research and Development Partnership III (the ``Partnership'') at December 31,
1996, and the results of its operations, the changes in its partners' capital
and its cash flows for the year then ended, in conformity with generally
accepted accounting principles. These financial statements are the
responsibility of the general partner; our responsibility is to express an
opinion on these financial statements based on our audit. We conducted our audit
of these statements in accordance with generally accepted auditing standards
which require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by the general partner, and evaluating the
overall financial statement presentation. We believe that our audit provides a
reasonable basis for the opinion expressed above.
/s/ Price Waterhouse LLP
3
Deloitte &
Touche LLP
--------------------------------------------------------
Two World Financial Center Telephone: (212) 436-2000
New York, New York 10281-1414 Facsimile: (212) 436-5000
INDEPENDENT AUDITORS' REPORT
To the Partners of
PruTech Research and Development Partnership III
We have audited the accompanying statement of financial condition of PruTech
Research and Development Partnership III (a California limited partnership) as
of December 31, 1995, and the related statements of operations, changes in
partners' capital and cash flows for each of the two years in the period ended
December 31, 1995. These financial statements are the responsibility of the
General Partner. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such financial statements present fairly, in all material
respects, the financial position of PruTech Research and Development Partnership
III as of December 31, 1995, and the results of its operations and its cash
flows for each of the two years in the period ended December 31, 1995 in
conformity with generally accepted accounting principles.
/s/ Deloitte & Touche LLP
February 13, 1996
- -----------------
Deloitte Touche
Tohmatsu
International
- -----------------
3A
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
STATEMENTS OF FINANCIAL CONDITION
December 31,
-----------------------------
1996 1995
- ----------------------------------------------------------------------------------------------------
ASSETS
Cash and cash equivalents $ 2,342,441 $ 480,692
Investments in equity securities 13,321,925 19,182,479
Other assets -- 216,669
------------ ------------
Total assets $15,664,366 $19,879,840
------------ ------------
------------ ------------
LIABILITIES AND PARTNERS' CAPITAL
Liabilities
Accrued management fee $ 204,670 $ 204,670
Accrued expenses and other liabilities 80,438 73,091
------------ ------------
Total liabilities 285,108 277,761
------------ ------------
Contingencies
Partners' capital
Unitholders (40,934 units issued and outstanding) 8,312,200 7,505,854
General partner 931,316 841,722
Unrealized gain on investments in equity securities 6,135,742 11,254,503
------------ ------------
Total partners' capital 15,379,258 19,602,079
------------ ------------
Total liabilities and partners' capital $15,664,366 $19,879,840
------------ ------------
------------ ------------
- ----------------------------------------------------------------------------------------------------
The accompanying notes are an integral part of these statements
4
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
STATEMENTS OF OPERATIONS
Year ended December 31,
------------------------------------------
1996 1995 1994
- ---------------------------------------------------------------------------------------------------
REVENUES
Gain on sale of investments in equity securities $ 5,194,202 $ 8,998,197 $2,364,352
Termination of royalty rights -- 2,241,783 --
Interest and other income 38,019 71,671 72,703
Royalty income 216,665 -- 50,468
Exclusive license fees -- -- 138,667
Monitoring fee income -- -- 80,377
----------- ----------- ----------
5,448,886 11,311,651 2,706,567
----------- ----------- ----------
EXPENSES
Management fee 818,680 818,680 818,680
General and administrative 92,116 111,655 227,772
Evaluation and monitoring 3,572 54,405 39,732
Interest -- 18,070 134,799
Write-down of investments in equity securities -- -- 500,000
Write-off of stock warrants -- -- 180,000
----------- ----------- ----------
914,368 1,002,810 1,900,983
----------- ----------- ----------
Net income $ 4,534,518 $10,308,841 $ 805,584
----------- ----------- ----------
----------- ----------- ----------
ALLOCATION OF NET INCOME
Unitholders $ 4,081,066 $ 9,277,957 $ 725,026
----------- ----------- ----------
----------- ----------- ----------
General partner $ 453,452 $ 1,030,884 $ 80,558
----------- ----------- ----------
----------- ----------- ----------
Net income per unit $ 99.70 $ 226.66 $ 17.71
----------- ----------- ----------
----------- ----------- ----------
- ---------------------------------------------------------------------------------------------------
STATEMENTS OF CHANGES IN PARTNERS' CAPITAL
UNREALIZED
GENERAL GAIN ON
UNITHOLDERS PARTNER INVESTMENTS TOTAL
- -----------------------------------------------------------------------------------------------------
Partners' capital--December 31, 1993 $4,973,326 $ 560,331 $ 26,110,075 $31,643,732
Net income 725,026 80,558 -- 805,584
Distribution (347,939 ) (38,660) -- (386,599)
Change in unrealized gain on
investments in equity securities -- -- (15,359,376) (15,359,376)
----------- ---------- ------------ -----------
Partners' capital--December 31, 1994 5,350,413 602,229 10,750,699 16,703,341
Net income 9,277,957 1,030,884 -- 10,308,841
Distributions (7,122,516 ) (791,391) -- (7,913,907)
Change in unrealized gain on
investments in equity securities -- -- 503,804 503,804
----------- ---------- ------------ -----------
Partners' capital--December 31, 1995 7,505,854 841,722 11,254,503 19,602,079
Net income 4,081,066 453,452 -- 4,534,518
Distributions (3,274,720 ) (363,858) -- (3,638,578)
Change in unrealized gain on
investments in equity securities -- -- (5,118,761) (5,118,761)
----------- ---------- ------------ -----------
Partners' capital--December 31, 1996 $8,312,200 $ 931,316 $ 6,135,742 $15,379,258
----------- ---------- ------------ -----------
----------- ---------- ------------ -----------
- -----------------------------------------------------------------------------------------------------
The accompanying notes are an integral part of these statements
5
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
STATEMENTS OF CASH FLOWS
Year ended December 31,
--------------------------------------------
1996 1995 1994
- -----------------------------------------------------------------------------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES
Royalty income received $ 216,665 $ 389,023 $ 101,996
Interest and other income received 38,019 71,671 72,703
Management fee paid (818,680) (1,637,360) (204,670)
General and administrative expenses paid (84,769) (100,558) (293,131)
Evaluation and monitoring expenses paid (3,572) (54,405) (66,046)
Interest paid -- (55,742) (100,266)
Cash received for other assets 216,669 -- --
Exclusive license fees received -- -- 138,667
----------- ------------ -----------
Net cash used in operating activities (435,668) (1,387,371) (350,747)
----------- ------------ -----------
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from the sale of investments in equity
securities 5,935,995 9,010,326 2,368,472
Proceeds from the termination of royalty rights -- 2,241,783 --
----------- ------------ -----------
Net cash provided by investing activities 5,935,995 11,252,109 2,368,472
----------- ------------ -----------
CASH FLOWS FROM FINANCING ACTIVITIES
Distributions (3,638,578) (7,913,907) (386,599)
Repayment of note payable -- (1,622,223) (1,584,000)
----------- ------------ -----------
Net cash used in financing activities (3,638,578) (9,536,130) (1,970,599)
----------- ------------ -----------
Net increase in cash and cash equivalents 1,861,749 328,608 47,126
Cash and cash equivalents at beginning of year 480,692 152,084 104,958
----------- ------------ -----------
Cash and cash equivalents at end of year $ 2,342,441 $ 480,692 $ 152,084
----------- ------------ -----------
----------- ------------ -----------
- -----------------------------------------------------------------------------------------------------
(continued on next page)
6
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
STATEMENTS OF CASH FLOWS (Cont'd)
Year ended December 31,
--------------------------------------------
1996 1995 1994
- -----------------------------------------------------------------------------------------------------
RECONCILIATION OF NET INCOME TO NET CASH USED IN
OPERATING ACTIVITIES
Net income $ 4,534,518 $ 10,308,841 $ 805,584
----------- ------------ -----------
Adjustments to reconcile net income to net cash used
in operating activities:
Gain on sale of investments in equity securities (5,194,202) (8,998,197) (2,364,352)
Termination of royalty rights -- (2,241,783) --
Monitoring fee income -- -- (80,377)
Write-down of investments in equity securities -- -- 500,000
Write-off of stock warrants -- -- 180,000
Changes in:
Royalties receivable -- 389,023 51,528
Accrued management fee -- (818,680) 614,010
Accrued expenses and other liabilities 7,347 (26,575) (57,140)
Deferred income -- -- (138,667)
Note receivable -- -- 138,667
Other assets 216,669 -- --
----------- ------------ -----------
Total adjustments (4,970,186) (11,696,212) (1,156,331)
----------- ------------ -----------
Net cash used in operating activities $ (435,668) $ (1,387,371) $ (350,747)
----------- ------------ -----------
----------- ------------ -----------
- -----------------------------------------------------------------------------------------------------
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING ACTIVITIES
1995
Exercised a warrant to acquire, on a net issuance basis, 171,635 shares of Interleaf, Inc. common
stock.
1994
The General Partner concluded that an impairment in value that was not temporary had occurred for the
Partnership's equity investment in Somatix Therapy Corporation. As a result, the value of the
Partnership's 500,000 shares of common stock was written down by $500,000.
The market value per share of Interleaf, Inc.'s common stock fell below the exercise price of the
stock warrants held by the Partnership. Accordingly, these warrants (cost basis of $180,000) were
written off.
- -----------------------------------------------------------------------------------------------------
The accompanying notes are an integral part of these statements
7
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
NOTES TO FINANCIAL STATEMENTS
A. General
PruTech Research and Development Partnership III (the ``Partnership''), a
California limited partnership, was formed on June 2, 1986 and will terminate on
December 31, 2006 unless terminated sooner under the provisions of the Agreement
of Limited Partnership (the ``Partnership Agreement''). Capital resources were
originally provided by the sale of depositary units and by contributions of the
General Partner equal to 10% of depositary contributions. The Partnership was
formed to seek cash flow from the research and development of new technologies
with potential commercial applications. The general partner of the Partnership
is R&D Funding Corp (the ``General Partner''), an affiliate of Prudential
Securities Incorporated (``PSI''). Both the General Partner and PSI are
wholly-owned subsidiaries of Prudential Securities Group Inc. (``PSGI''). The
assignor limited partner is Prudential-Bache Investor Services Inc., an
affiliate of the General Partner, who has assigned substantially all the rights
attributable to its limited partnership interest to investors. At December 31,
1996, the Partnership held equity investments or active royalty rights relating
to four portfolio companies.
B. Summary of Significant Accounting Policies
Basis of accounting
The books and records of the Partnership are maintained on the accrual basis
of accounting in accordance with generally accepted accounting principles.
The preparation of financial statements in conformity with generally accepted
accounting principles requires the General Partner to make estimates and
assumptions that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the financial
statements as well as the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents
Cash and cash equivalents include money market funds.
Investments
The Partnership's equity securities that have readily determinable fair
values are classified as available-for-sale securities. These securities are
measured at fair value in the statements of financial condition and unrealized
gains and losses are reported as a separate component of partners' capital.
Equity securities traded on a national securities exchange or the NASDAQ
national market are valued at the last reported sales price on the primary
exchange on which they are traded. Equity securities traded in the
over-the-counter market and thinly-traded securities are valued at the mean
between the last reported bid and asked prices. Equity securities which are not
readily marketable are accounted for under the cost method.
The carrying value of an investment is written down to its fair value when a
decline in value is considered to be other than temporary. The Partnership uses
the average cost method to determine gains or losses on the sale of securities.
Royalty income
Royalty income represents revenue generated from licenses granted by the
Partnership.
Monitoring fee income
Payments received from research and development companies to reimburse the
Partnership for its cost of monitoring during the development and marketing
periods of a product were deferred and fully amortized over an eight year-period
which ended December 31, 1994.
8
Management fee
The General Partner is paid a management fee equal to two percent of the
unitholders' original capital contributions per annum. This fee provides for the
cost of overseeing, supervising and monitoring the conduct of the development
projects and for overseeing and monitoring product exploitation resulting from
the development projects.
Income taxes
The Partnership is not required to provide for, or pay, any Federal or state
income taxes. Income tax attributes that arise from its operations are passed
directly to the individual partners. The Partnership may be subject to other
state and local taxes in jurisdictions in which it operates.
Profit and loss allocations and distributions
Profits and losses are allocated 90% to the unitholders and 10% to the
General Partner in proportion to their capital accounts until such time as the
total net profits allocated to each unitholder equal all losses previously
allocated whereupon the General Partner will be allocated net profits in an
additional amount of 25% with a corresponding reduction to the unitholders to be
shared in proportion to their capital contributions.
Distributions of cash are made in accordance with the Partnership Agreement
and are allocated 90% to the unitholders and 10% to the General Partner.
C. Royalties
On April 1, 1990 the Partnership entered into a Technology Development
Investment Agreement with Kopin Corporation (``Kopin'') for the development of
LED technology. Pursuant to the Agreement, Kopin was obligated to pay to the
Partnership royalties on the sale of products containing the technology through
April 1, 1996, with a minimum royalty payment of $433,334 due April 1, 1996
(payable in cash or by the delivery of a promissory note). Kopin agreed to pay
cash for the minimum royalty because the Partnership also agreed to transfer to
Kopin its Gas technology developed under an earlier contract. During the second
quarter of 1996, the Partnership received the $433,334 minimum royalty payment
of which $216,669 represented a reduction of its receivable from Kopin and
$216,665 was recorded as royalty income. As a result, the Partnership holds no
technology or royalty positions with Kopin and, therefore, no further royalties
will be received by the Partnership from Kopin.
In November 1995, the Partnership and Interleaf, Inc. (``Interleaf'') agreed
to settle all royalty and other disputes between them and the Partnership sold
to Interleaf the Partnerships' right, title and interest in technology licensed
to Interleaf for $2,100,000. In connection with this transaction, the
Partnership applied $375,081 of the proceeds to its outstanding royalty
receivable balance and the remaining $1,724,919 was recognized as income. During
1995, revenues from Interleaf inclusive of the gain on common stock sold (see
Note D) represented approximately 32% of the Partnership's total 1995 revenues.
In March 1995, the Partnership and the MacNeal-Schwendler Corporation
(``MNS'') agreed to terminate the Partnership's contractual rights with respect
to MNS software and to transfer the technology relating to the software to MNS
in exchange for $516,870. No further royalty payments will be received by the
Partnership from MNS as a result of this agreement.
The Partnership retains certain royalty rights with Forest Laboratories, Inc.
and Creative Biomolecules, Inc. whose carrying values at December 31, 1996 are
zero.
D. Investments
In connection with certain of its research and development contracts, the
Partnership has exercised its warrants or has converted its technology, royalty
rights, warrants or notes receivable into an equity position in the companies
performing the research and development.
9
Investments in equity securities available-for-sale at December 31, 1996 and
1995 include the following:
1996 1995
-------------------------------------------------- --------------------------------------------------
Gross unrealized Carrying Gross unrealized Carrying
Shares Cost basis gains value Shares Cost basis gains value
- ------------------------------------------------------------------------- --------------------------------------------
Creative BioMolecules,
Inc.-Common Stock 509,382 $1,666,928 $3,617,910 $ 5,284,838 724,282 $2,370,177 $ 2,699,797 $ 5,069,974
Forest Laboratories,
Inc.-
Common Stock -- -- -- -- 75,000 6,130 3,387,620 3,393,750
Kopin Corporation-
Common Stock 537,333 4,019,255 2,361,582 6,380,837 541,667 4,051,669 3,667,086 7,718,755
Somatix Therapy
Corporation-
Common Stock 500,000 1,500,000 156,250 1,656,250 500,000 1,500,000 1,500,000 3,000,000
---------- ---------------- ----------- ---------- ---------------- -----------
$7,186,183 $6,135,742 $13,321,925 $7,927,976 $ 11,254,503 $19,182,479
---------- ---------------- ----------- ---------- ---------------- -----------
---------- ---------------- ----------- ---------- ---------------- -----------
The gross unrealized gains would be allocated 90% to the unitholders and 10%
to the General Partner if realized at December 31, 1996; however, there is no
assurance that the Partnership would receive these amounts in the event of the
sale of its position in these securities.
Creative BioMolecules, Inc.
During December 1996, the Partnership sold 214,900 shares of Creative
BioMolecules, Inc. common stock with a cost basis of approximately $703,000
resulting in a gain of approximately $1,573,000. During 1996, revenues from the
Partnership's investment in Creative BioMolecules, Inc. represented
approximately 29% of the Partnership's total 1996 revenues.
Subsequent to December 31, 1996, the Partnership sold 441,898 shares of
Creative BioMolecules, Inc. common stock as more fully discussed in Note I.
Forest Laboratories, Inc.
During the first quarter of 1996, the Partnership sold its remaining 75,000
shares of Forest Laboratories, Inc. common stock with a cost basis of
approximately $6,000 resulting in a gain of approximately $3,594,000. During
1996, revenues relating to the Partnership's investment in Forest Laboratories,
Inc. represented approximately 66% of the Partnership's total 1996 revenues.
During the first quarter of 1995, the Partnership sold 88,000 shares of
Forest Laboratories, Inc. common stock with a cost basis of approximately $7,000
resulting in a gain of approximately $4,256,000. During the third quarter of
1995, the Partnership sold 60,410 shares of Forest Laboratories, Inc. common
stock with a cost basis of approximately $5,000 resulting in a gain of
approximately $2,864,000. During 1995, revenues relating to the Partnership's
investment in Forest Laboratories, Inc. represented approximately 63% of the
Partnership's total revenues.
In January 1994, the Partnership sold 50,393 shares of Forest Laboratories,
Inc. common stock with a cost basis of approximately $4,000 resulting in a gain
of approximately $2,364,000.
Kopin Corporation
During the first quarter of 1996, the Partnership sold 4,334 shares of Kopin
Corporation common stock with a cost basis of approximately $32,000 resulting in
a gain of approximately $27,000.
Subsequent to December 31, 1996, the Partnership sold 82,189 shares of Kopin
Corporation common stock as more fully discussed in Note I.
Somatix Therapy Corporation
In 1994, the General Partner concluded that an impairment in value that was
not temporary had occurred for the Partnership's equity investment in Somatix
Therapy Corporation. As a result, the value of the Partnership's common stock
was written down by $500,000.
Subsequent to December 31, 1996, the Partnership sold 205,000 shares of
Somatix Therapy Corporation common stock as more fully discussed in Note I.
10
Interleaf, Inc.
In July 1995, the Partnership exercised a warrant to acquire, on a net
issuance basis, 171,635 shares of Interleaf, Inc. common stock. In August 1995,
the Partnership sold 25,000 of the company's shares resulting in a gain of
approximately $250,000. In November 1995, the Partnership sold the remaining
146,635 of the company's shares which resulted in a gain of approximately
$1,628,000.
In 1994, the market value per share of Interleaf, Inc.'s common stock fell
below the exercise price of the stock warrants held by the Partnership.
Accordingly, these warrants (cost basis of $180,000) were written off in 1994
and subsequently expired in 1995.
E. Note Payable
In December 1993, the Partnership issued a note to Creative BioMolecules,
Inc. with a principal value of $1,622,223 to exercise an expiring warrant to
purchase common stock. The note accrued interest at 7.0%. Principal and interest
($55,741) were repaid in February 1995.
F. Income Taxes
The following is a reconciliation of net income for financial reporting
purposes to net income for tax reporting purposes:
Year ended December 31,
-----------------------------------------
1996 1995 1994
-----------------------------------------
Net income per financial statements $4,534,518 $10,308,841 $ 805,584
Write-off of investment in equity securities (511,194) (66,668) 500,000
Royalty income (76,698) -- --
Expiration of stock warrants -- (180,000) --
Write-off of stock warrants -- -- 180,000
Monitoring fee income -- -- (80,377)
Amortization of evaluation fees -- -- (3,346)
---------- ----------- ----------
Tax basis net income $3,946,626 $10,062,173 $1,401,861
---------- ----------- ----------
---------- ----------- ----------
The differences between the tax basis and book basis of partners' capital are
primarily attributable to the cumulative effect of the book to tax income
adjustments.
G. Related Parties
The General Partner and its affiliates perform certain services for the
Partnership for which they are reimbursed through the management fee which
include, but are not limited to: accounting and financial management; registrar,
transfer and assignment functions; asset management; investor communications and
other administrative services. The Partnership also reimburses an affiliate of
the General Partner for printing services. The costs and expenses were:
Year ended December 31,
----------------------------------
1996 1995 1994
----------------------------------
Management fee $818,680 $818,680 $818,680
Printing 11,849 18,691 7,277
-------- -------- --------
$830,529 $837,371 $825,957
-------- -------- --------
-------- -------- --------
Printing costs payable to an affiliate of the General Partner (which are
included in accrued expenses) as of December 31, 1996 and 1995 were $4,943 and
$16,464, respectively.
Prudential Securities Incorporated, an affiliate of R&D Funding Corp, owned
724 units in the Partnership at December 31, 1996.
The Partnership maintains an account with the Prudential Institutional
Liquidity Portfolio Fund, an affiliate of R&D Funding Corp, for investment of
its available cash in short-term instruments pursuant to the guidelines
established by the Partnership Agreement.
11
The Partnership has engaged in research and development co-investment
projects with PruTech Research and Development Partnership, PruTech Research and
Development Partnership II and PruTech Project Development Partnership
(collectively, the ``PruTech R&D Partnerships''), for which R&D Funding Corp
serves as the general partner. The allocation of the co-investment projects'
profits or losses among the PruTech R&D Partnerships is consistent with the
costs incurred to fund the research and development projects.
H. Contingencies
On April 15, 1994, a multiparty petition captioned Mack et al. v. Prudential
Securities Incorporated et al. (Cause No. 94-17695) was filed in the 80th
Judicial District Court of Harris County, Texas, purportedly on behalf of
investors in the Partnership against the Partnership, the General Partner,
Prudential Securities Incorporated, The Prudential Insurance Company of America
and a number of other defendants. The petition alleges common law fraud and
fraud in the inducement and negligent misrepresentation in connection with the
offering of the Partnership units; negligence and breach of fiduciary duty in
connection with the operation of the Partnership; civil conspiracy; and
violations of the federal Securities Act of 1933 (sections 11 and 12), and of
the Texas Securities and Deceptive Trade Practices statutes. The suit seeks,
among other things, compensatory and punitive damages, costs and attorneys'
fees. The ultimate outcome of this litigation as well as the impact on the
Partnership cannot presently be determined.
The General Partner, Prudential Securities Incorporated and the Partnership
believe they have meritorious defenses to the complaint and intend to vigorously
defend themselves in this action.
I. Subsequent Events
During January and February 1997, the Partnership sold 441,898 shares of
Creative BioMolecules, Inc. common stock for approximately $5,019,000 which
resulted in a gain of approximately $3,572,000.
From January 15, 1997 through March 14, 1997, the Partnership sold 82,189
shares of Kopin Corporation common stock for approximately $1,037,000 which
resulted in a gain of approximately $423,000.
Between January 28, 1997 and February 3, 1997, the Partnership sold 205,000
shares of Somatix Therapy Corporation common stock for approximately $517,000
which resulted in a loss of approximately $98,000.
In February and in March of 1997, the Partnership made distributions of
$4,548,222 and $3,411,167, respectively, of which $4,093,400 ($100 per unit) and
$3,070,050 ($75 per unit), respectively, were paid to the limited partners, and
the remainder to the General Partner.
12
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Liquidity and Capital Resources
As of December 31, 1996, the Partnership had approximately $2,342,000 of cash
and cash equivalents which is an increase of approximately $1,862,000 as
compared to December 31, 1995. This increase is primarily due to proceeds from
the sales of the Partnership's common stock offset, in part, by the January 1996
distribution as discussed below.
As of December 31, 1996, the Partnership had approximately $7.2 million
invested in equity securities with an aggregate market value which exceeded its
cost. Certain of these investments are in development stage companies which are
more speculative and higher in risk than other equity investments. Additionally,
the realization of this market value is further impacted by certain sale
restrictions and market volume capacity. The amount to be distributed by the
Partnership in future quarters will be based on the extent to which the market
value of its investments can be realized and, to a lesser extent, from the
revenue stream from royalties and interest income. It is not expected that the
Partnership's eventual total distributions will equal the Unitholders' initial
investments. Except for royalty income from Kopin Corporation (``Kopin'') in
1996 as further discussed below, the Partnership's royalty positions did not
generate royalty income for the Partnership during 1996 and 1995.
In January 1996, the Partnership sold its remaining 75,000 shares of Forest
Laboratories, Inc. (``Forest'') common stock for approximately $3,600,000. The
proceeds from the sale were used to pay a distribution of approximately
$3,639,000 in January 1996. Unitholders received a total of approximately
$3,275,000 ($80 per unit) and the General Partner received the remainder. The
Partnership has retained its royalty position with Forest.
Also, during the first quarter of 1996, the Partnership sold 4,334 shares of
Kopin common stock for approximately $60,000.
On April 1, 1990 the Partnership entered into a Technology Development
Investment Agreement with Kopin for the development of LED technology. Pursuant
to the Agreement, Kopin was obligated to pay to the Partnership royalties on the
sale of products containing the technology through April 1, 1996, with a minimum
royalty payment of $433,334 due April 1, 1996 (payable in cash or by the
delivery of a promissory note). Kopin agreed to pay cash for the minimum royalty
because the Partnership also agreed to transfer to Kopin its GaAs technology
developed under an earlier contract. During the second quarter of 1996, the
Partnership received the $433,334 minimum royalty payment of which $216,669
represented a reduction of its receivable from Kopin and $216,665 was recorded
as royalty income. As a result of the above, the Partnership holds no technology
or royalty positions with Kopin and, therefore, no further royalties will be
received by the Partnership from Kopin.
During December 1996, the Partnership sold 214,900 shares of Creative
BioMolecules, Inc. common stock for proceeds of approximately $2,276,000.
Subsequent to 1996, the Partnership sold 441,898 shares of Creative
BioMolecules, Inc. common stock for approximately $5,019,000, 82,189 shares of
Kopin Corporation common stock for approximately $1,037,000 and 205,000 shares
of Somatix Therapy Corporation common stock for approximately $517,000.
Additionally, in February and in March of 1997, the Partnership made
distributions of $4,548,222 and $3,411,167, respectively, of which $4,093,400
($100 per unit) and $3,070,050 ($75 per unit), respectively, were paid to the
limited partners, and the remainder to the General Partner.
Results of Operations
Net income for the years ended December 31, 1996, 1995 and 1994 was
approximately $4,535,000, $10,309,000 and $806,000, respectively. The primary
reasons for the fluctuations in operating results are discussed below.
During 1996, the Partnership recorded gains of approximately $3,594,000 and
$1,573,000 on the sale of 75,000 shares of Forest Laboratories, Inc. common
stock and 214,900 shares of Creative BioMolecules, Inc.
13
common stock, respectively. During 1995, the Partnership recorded gains of
approximately $7,121,000 and $1,878,000, respectively, on the sale of 148,410
shares of Forest common stock and 171,635 shares of Interleaf, Inc.
(``Interleaf'') common stock. In January 1994, the Partnership sold 50,393
shares of Forest Laboratories, Inc. common stock resulting in a gain of
approximately $2,364,000.
In November 1995, the Partnership and Interleaf agreed to settle all royalty
and other disputes between them and to sell to Interleaf its right, title and
interest in technology licensed to Interleaf for $2,100,000. In connection with
this transaction, the Partnership applied $375,000 of the proceeds to its
outstanding royalty receivable balance and the remaining $1,725,000 was
recognized as income. In March 1995, the Partnership and the MacNeal-Schwendler
Corporation (``MNS'') agreed to terminate the Partnership's contractual rights
with respect to MNS software and to transfer the technology relating to the
software to MNS in exchange for approximately $517,000. No further royalty
payments will be received by the Partnership from Interleaf or MNS as a result
of these agreements.
No royalties were earned by the Partnership in 1995. Royalty income for the
year ended December 31, 1996 was approximately $217,000 and relates to the Kopin
transaction as discussed above. Royalty income of approximately $50,000 was
generated during the year ended December 31, 1994 from the Partnership's royalty
positions, including the MacNeal-Schwendler Corporation royalty position which
was terminated in March 1995.
During the fourth quarter of 1989, the Partnership accepted a $138,667 note
receivable from Kopin Corporation in lieu of payment of exclusive license fees.
This note plus accrued interest (which was previously deferred) was collected
during the fourth quarter of 1994 and recognized as income.
In 1994, the General Partner concluded that an impairment in value that was
not temporary had occurred for the Partnership's equity investment in Somatix
Therapy Corporation. As a result, the value of the Partnership's common stock
was written down by $500,000. Also in 1994, the market value per share of
Interleaf common stock fell below the exercise price of the stock warrants held
by the Partnership. Accordingly, these warrants (cost basis of $180,000) were
written off in 1994 and subsequently expired in 1995.
General and administrative expenses for the year ended December 31, 1996
decreased by approximately $20,000 as compared to 1995 and decreased by
approximately $116,000 for the year ended December 31, 1995 as compared to 1994
primarily due to legal costs incurred in 1994, and, to a lesser extent, in 1995
in connection with the Interleaf royalty contract dispute.
Evaluation and monitoring expenses decreased by approximately $51,000 for the
year ended December 31, 1996 as compared to 1995 but increased by approximately
$15,000 for the year ended December 31, 1995 as compared to 1994. The 1996
decrease was due to lower levels of overall activity in the Partnership's R&D
projects and license agreements during 1996. The 1995 increase was primarily due
to the use of consultants in 1995 related to the royalty dispute with Interleaf.
Interest expense on the Creative BioMolecules, Inc. note, which was repaid in
February 1995, was approximately $18,000 and $135,000 for the years ended
December 31, 1995 and 1994, respectively, as more fully discussed in Note E to
the financial statements.
Inflation
Inflation has had no direct material impact on operations or on the financial
condition of the Partnership from inception through December 31, 1996.
14
OTHER INFORMATION
The Partnership's Annual Report on Form 10-K as filed with the Securities and
Exchange Commission is available to limited partners without charge upon written
request to:
PruTech Research and Development Partnership III
P.O. Box 2016
Peck Slip Station
New York, New York 10272-2016
15
Peck Slip Station BULK RATE
P.O. Box 2016 U.S. POSTAGE
New York, NY 10272 PAID
Automatic Mail
PRUTEC386/170864